Omeros Corporation - Asset Resilience Ratio
Omeros Corporation (OMER) has an Asset Resilience Ratio of 46.62% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2007–2025)
This chart shows how Omeros Corporation's Asset Resilience Ratio has changed over time. Check strategic asset allocation of Omeros Corporation to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Omeros Corporation's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see OMER stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $133.41 Million | 46.62% |
| Total Liquid Assets | $133.41 Million | 46.62% |
Asset Resilience Insights
- Very High Liquidity: Omeros Corporation maintains exceptional liquid asset reserves at 46.62% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Omeros Corporation Industry Peers by Asset Resilience Ratio
Compare Omeros Corporation's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for Omeros Corporation (2007–2025)
The table below shows the annual Asset Resilience Ratio data for Omeros Corporation.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 49.79% | $162.14 Million | $325.63 Million | +18.49pp |
| 2024-12-31 | 31.30% | $86.73 Million | $277.08 Million | -12.25pp |
| 2023-12-31 | 43.55% | $164.74 Million | $378.27 Million | +12.43pp |
| 2022-12-31 | 31.12% | $183.91 Million | $590.97 Million | +17.65pp |
| 2021-12-31 | 13.47% | $56.46 Million | $419.27 Million | -55.28pp |
| 2020-12-31 | 68.74% | $124.45 Million | $181.04 Million | +26.61pp |
| 2019-12-31 | 42.13% | $57.70 Million | $136.97 Million | -14.82pp |
| 2018-12-31 | 56.95% | $54.64 Million | $95.94 Million | -12.12pp |
| 2017-12-31 | 69.08% | $80.36 Million | $116.33 Million | +5.00pp |
| 2016-12-31 | 64.07% | $43.11 Million | $67.28 Million | +9.17pp |
| 2015-12-31 | 54.90% | $26.90 Million | $48.99 Million | -4.00pp |
| 2014-12-31 | 58.90% | $6.53 Million | $11.09 Million | -18.01pp |
| 2013-12-31 | 76.91% | $12.72 Million | $16.54 Million | -1.47pp |
| 2012-12-31 | 78.38% | $20.83 Million | $26.57 Million | +2.16pp |
| 2011-12-31 | 76.22% | $20.57 Million | $26.98 Million | -8.49pp |
| 2010-12-31 | 84.71% | $38.72 Million | $45.70 Million | -11.14pp |
| 2009-12-31 | 95.85% | $59.48 Million | $62.06 Million | +62.38pp |
| 2008-12-31 | 33.47% | $7.26 Million | $21.68 Million | -33.38pp |
| 2007-12-31 | 66.85% | $18.16 Million | $27.16 Million | -- |
About Omeros Corporation
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinic… Read more